rs1051266 — SLC19A1 G80A (His27Arg)
Folate transporter — how well folate gets into your cells
Details
- Gene
- SLC19A1
- Chromosome
- 21
- Risk allele
- T
- Protein change
- p.His27Arg
- Consequence
- Missense
- Inheritance
- Codominant
- Clinical
- Risk Factor
- Evidence
- Moderate
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Tags
Related SNPs
Category
Methylation & DetoxSLC19A1 — The Folate Gateway
SLC19A1 (Solute Carrier Family 19 Member 1), also known as the reduced folate carrier (RFC1), is the primary transporter responsible for moving folate from your blood into your cells. Even if you produce adequate methylfolate (via MTHFR) or take methylfolate supplements, this transporter determines how efficiently that folate actually reaches the inside of your cells where it is needed.
The Mechanism
The G80A variant (rs1051266) causes a histidine-to-arginine substitution 11 Histidine-to-arginine substitution at position 27 of the transporter protein (p.His27Arg) at position 27 of the transporter protein, located in transmembrane domain 1 (TMD1), a region implicated in substrate binding and translocation. The T allele (arginine variant) has altered transport kinetics, resulting in reduced folate uptake into cells. This creates a situation where blood folate levels may appear normal on a standard test, but intracellular folate levels are suboptimal.
Clinical Relevance
This variant is particularly important in the context of other methylation
variants. If you have reduced MTHFR activity (making less methylfolate) AND
reduced RFC1 transport (getting less folate into cells), the combined effect
can be more significant than either variant alone. Studies have also linked
this variant to altered methotrexate response 22 Methotrexate is an antifolate drug used for cancer and autoimmune diseases — it competes with folate for the same RFC1 transporter, since methotrexate uses the
same transporter. A PharmGKB summary33 A PharmGKB summary
Gong L et al. SLC19A1 Pharmacogenomics Summary, 2010
documents the pharmacogenomic relevance of this transporter.
The Bigger Picture
The folate pathway is like a production line: MTHFR converts folate to its active form, SLC19A1 transports it into cells, and MTHFD1 helps process it further. Bottlenecks at any step can reduce overall methylation capacity 44 This is why looking at individual SNPs in isolation can be misleading — the whole pathway matters. By understanding which steps are compromised, you can target your supplementation more effectively.
Practical Implications
If you carry the T allele, ensuring adequate (or slightly above average) folate intake becomes important. Methylfolate may have an advantage over folic acid since it is already in the active form and may be transported more efficiently. Higher doses may help compensate for reduced transport efficiency.
Interactions
SLC19A1 interacts with MTHFR (rs1801133, rs1801131) — if both folate production and transport are impaired, the combined effect is greater. It also interacts with MTHFD1 (rs2236225) for downstream folate processing.
Drug Interactions
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Normal folate transport
You have normal folate transporter function. Your cells can efficiently import folate from your bloodstream. About 28% of Europeans share this genotype.
Mildly reduced folate transport
You carry one variant allele, which may reduce folate transport into cells by about 25%. This becomes more relevant if you also have MTHFR variants. About 50% of people share this genotype.
Reduced folate transport into cells
You have two copies of the transport variant. Even if blood folate levels are normal, less may be getting into your cells. About 22% of people share this genotype.
Key References
PharmGKB summary of SLC19A1 pharmacogenomics including methotrexate transport
SLC19A1 rs1051266 associated with protection from methotrexate toxicity in rheumatoid arthritis
Original functional characterization of reduced folate carrier His27Arg variant
SLC19A1 polymorphisms and folate transport efficiency in cell models